The company, established as a merger between A*STAR MedTech spin-off MiRXES and venture capital firm Venturecraft, has developed a blood test for early-stage stomach cancer.
Count Me In is aiming to sign up more than 100,000 patients across all major cancer types, as well as rare cancers, over the next several years.
A phylogenetic analysis that included multiple samples per patient suggests overlapping driver mutations make their way into multiple metastases in each patient.
Physicians can now use the Dako PD-L1 IHC 22C3 pharmDx assay to identify urothelial carcinoma patients who may benefit from the anti-PD1 immunotherapy.
An international team of researchers also suggested that MUC16 mutations could identify patients who might benefit from immunotherapy treatment.
A Samsung University team found that mutation load measured with the Guardant360 liquid biopsy assay predicted response as well as tissue-based TMB.
While the '3G' study did not establish clinical utility, the researchers said it shows genomic profiling to guide gastric cancer treatment is feasible.
Five Prime will use an IHC CDx to analyze the use of investigational drug candidates in patients with advanced gastric or gastroesophageal junction cancer.
The ctDNA assay will be used to select patients for Phase 3 of Five Prime's registrational trial investigating bemarituzumab in gastric cancer patients.
A proteomic and targeted exome sequencing study of diffuse-type gastric cancer led to proteomic subtypes with distinct mutation, survival, and potential treatment patterns.
The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.
The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.
Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.
In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.